Aim: Dendritic cells rapidly capture nanoparticles and induce a potent cellular immune response. It is yet unknown whether the immunological response induced by slow release of encapsulated versus soluble antigen and adjuvant is superior. Materials & methods: The kinetics of poly(lactic-co-glycolic acid) PLGA nanoparticles antigen release was studied by the DQ-bovine serum albumin (BSA) self-quenching antigen model. The immunological response induced was evaluated by means of dendritic cell activation/maturation markers, cytokine production and their ability to drive antigenspecific T-cell proliferation. Results & conclusion: PLGA-encapsulated antigen and adjuvant showed an enhanced T-cell response when compared with soluble vaccine components by increasing antigenicity and adjuvanticity. Although the kinetic profile followed the same pattern, encapsulation increased strength and duration of the response.
Classic prophylactic vaccines represent one of the most cost-effective public health interventions. Initially, farm animals and humans were inoculated with serous fluid of infected individuals. Later, artificially weakened pathogens were used, followed by the addition of adjuvants [1] . Several of these adjuvants act by generating an antigen depot at the site of injection, from which the antigen is slowly released and taken up by antigen presenting cells (APCs), resulting in a sustained immune activation. In a similar way, antigens encapsulated within microparticles, composed of biodegradable slow-release polymers, such as PLGA, elicit long-lived immunity against the antigen.
The classical prophylactic vaccines mainly focus on induction of long-lived T helper cell dependent IgG responses. However, therapeutic vaccines for treatment of chronic infections and cancer require strong proinflammatory CD4
+ and CD8 + T-cell responses. Many antigens expressed by the tumor are mutated, with little differences with respect to their normal counterparts, and are therefore not, or only poorly recognized by T cells. In addition, rare antigens, such as fetal antigens, are newly expressed in tumor cells due to genetic variability, and are poorly immunogenic. In contrast to pathogens, tumors usually lack danger signals such as Toll-like receptor (TLR) ligands that strongly activate and mature APC. Therefore, immunological therapies designed against cancer must 'trick' the immune system into believing that it is facing an infectious agent to induce a strong immune response.
On the other hand, soluble cancer antigens in nonencapsulated vaccines could be dispersed throughout the body fluids thereby reducing half-life. Similarly, soluble adjuvants might activate inappropriate (nonantigen presenting) cells resulting in cytokine-related toxicity. Therefore, encapsulation of antigen and TLR ligands into PLGA nanoparticles (NPs) is considered a promising tool for antitumor therapy as it addresses all these issues. PLGA NPs protect vaccine components against degradation and ensure targeting to specific receptors on dendritic cells (DCs) to trigger maturation and induction of an antitumor response.
Tumor cells and their niche microenvironment may produce factors inducing a negative imbalance of the immune response, both by direct suppression of T-cell activity and enhancing local Treg-mediated immunosuppression, which counteract the vaccine activating effect. Furthermore, several clinical investigations show that the frequency of Treg cells in tumors correlate with poor clinical outcome. To prevent this inhibitory effect, a strong immune response, as those induced by TLR ligands is required [2] [3] [4] [5] , or other strategies to block inhibitory factors or Treg cells, could be added to the NP formulations in order to enhance the effectiveness of tumor immunotherapy [6, 7] .
DCs, the key APCs of the immune system, elicited strong T-cell responses in the presence of TLR ligands. DCs are specialized in capturing nano-sized pathogens, such as bacteria and viruses. Larger particles do not pass through endothelial cell junctions, but are transported into the lymph vessel following uptake by DCs. Similar to pathogens, nano-sized vaccine carriers are preferentially scavenged by DCs and induce potent cellular and humoral immune responses [8] . Antigens encapsulated within biodegradable PLGA NPs induce potent CD4
+ and CD8 + T-cell responses provided that a 'danger signal,' such as a pathogen associated molecular pattern or cytokine is co-encapsulated to activate DCs. An additional advantage of using NPs is that they can be specifically targeted to DCs [9] . Thereby, NPs are coated with ligands or antibodies recognizing DCspecific receptors, which increases vaccine efficacy [10] . In this study, we encapsulated antigen together with ligand (TLRL) resiquimod (R848) (TLR7/8), a potent immunostimulatory agent, which mimics pathogenderived material and behavior by triggering endosomal TLRs.
Remarkably little is known about the long-term effect of slow antigen and adjuvant release following NP uptake by DCs. A variety of studies investigated the effect of slow antigen-release up to day 1-2 postantigen/adjuvant challenge [11, 12] , but almost no investigations were carried out at later time points (day [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . The question remains whether slow release of antigen and adjuvant, by means of endocytosed vaccine carriers, such as PLGA NPs, is beneficial or detrimental for vaccine efficacy, in comparison to soluble antigen/adjuvant deposited within the tissue. In this study, we used soluble versus encapsulated tetanus toxoid (TT) peptide and ovalbumin (ova) protein as model antigens in combination with the TLR7/8 ligand R848 as adjuvant, to examine the kinetics of antigen delivery, antigen processing, DC maturation, antigen presentation and cytokine release after endocytosis over a prolonged period of time both in primary mouse bone marrow-derived DCs (BMDCs) and primary humans DCs. The results suggest that encapsulation by itself increases antigenicity and adjuvanticity. We also provide biochemical evidence that antigen delivered by NPs are able to escape endosomal/lysosomal compartments and reach the cytoplasm at a significantly higher level than soluble antigens. Even though the kinetics of antigen presentation, activation, and cytokine production were similar between soluble and encapsulated antigens/ adjuvants as expected, the response to soluble vaccine components was in general lower and declined more rapidly compared with the encapsulated components, usually showing more significant differences at later time points. O) 99%, ammonium hydroxide (5 M) and oleic acid were purchased from Fisher Scientific (USA). R848 was from Axorra and antibodies: antihuman CD80 (BD Biosciences), antihuman CD83 (Beckman Coulter), antihuman CD86 (BD Biosciences). DQ Green BSA (DQ-BSA) was from Molecular Probes (The Netherlands).
Materials & methods

Materials
Peptide synthesis
The TT epitope comprises the 830-844 region of TT. FITC and TT epitopes were linked by a LysLys cathepsin-like cleavage site. The peptide antigen (FITC-KKQYIKANSKFIGITEL-COOH) [13] with the N-terminal modified with FITC was synthesized manually according to standard protocols of solidphase peptide synthesis, using the Fmoc/tert-butyl strategy and ClTrtCl resin. Nα-Fmoc-protected amino acids were incorporated using 1-hydroxybenzotriazole (HOBt) and N,N′-diisopropylcarbodiimide (DIPCDI) in DMF for 1.5 h and monitored by Kaiser ninhydrin tests [14] . The Fmoc-protecting group was cleaved with a 20% piperidine solution in DMF (2 × 10 min). After completion of the sequence, the peptide-resin was labeled with FITC (5 equiv.) and N,N-diisopropylethylamine (DIEA) (10 equiv.) in a 9:1 mixture of DMF:DCM and then added to the peptide-resin and stirred for 12 h. The fluorescein isothiocyanate tetanus toxoid (FITC-TT) peptide was cleaved from the ClTrtCl resin with TFA-DCM (1:99). The cleavage solution was removed by evaporation under reduced pressure. The lateral chains were completely removed by treatment with TFA:H 2 O:TES (95:2.5:2.5 v/v/v) for 2 h. The crude peptide product showed purity greater than 95% by RP-HPLC.
Preparation of particles SPIO
Superparamagnetic iron oxide (SPIO) were fabricated as described by Kumar et al. In brief [15] , SPIO were synthesized under inert atmospheric conditions through reduction of FeCl 3 and FeCl 2 salts using NH 4 OH solution at room temperature to obtain a black precipitate of SPIO. SPIO was encapsulated in PLGA NPs for intracellular tracking.
Nanoparticle preparation
PLGA NPs with entrapped FITC-TT peptide or OVA or DQ-bovine serum albumin (BSA) or R848 or SPIO were prepared using an o/w emulsion and solvent evaporation-extraction method [16] . In brief, 90 mg of PLGA in 3 ml of DCM containing the FITC-TT peptide (2 mg) or OVA (2 mg) or DQ-BSA (1 mg) or R848 (1 mg) or SPIO (10 mg/ml, 0.5 ml) were added dropwise to 25 ml of aqueous 2% (w/v) polyvinyl alcohol (PVA) in distilled water and emulsified for 90 s using a sonicator (Branson, sonifier 250). The DCM was removed by overnight evaporation at 4°C, the particles were collected by centrifugation at 17000 × g for 30 min, washed three-times with distilled water and lyophilized. Distinct antigens entrapment efficiency was determined by digesting 10 mg particles in 1 ml 0.8 mol/l NaOH overnight at 37°C. The FITC-TT content was determined by measuring fluorescence relative to a standard curve (excitation: 485 nm; emission: 530 nm) using the CytoFluor II (Applied Biosystems, USA). The amount of SPIO was determined by weighing after lyophilized samples of the preparation and the SPIO was determined. Entrapment efficiency of OVA and DQ-BSA was determined by Coomassie Plus Protein Assay Reagent (Pierce) according to the manufacturer's protocol. Antigen entrapment efficiency was determined by dividing the amount of the encapsulated antigen by the theoretical amount corresponding to full encapsulation. The R848 entrapment efficiency was determined by HPLC as previously described [17] (see Table 1 ).
Scanning electron microscopy NP morphology was studied by scanning electron microscopy. Particles were transferred to metallic stubs with double-sided conductive tape. Subsequently, samples were ion-coated with gold with a sputter coater (EDWARDS, Scan Coat, UK) for 180 s in a vacuum at a current intensity of 40 mA. Samples were analyzed on a Jeol JSM-6310 scanning electron microscope.
Dynamic light scattering & ζ potential
Dynamic light scattering measurements on particles were performed on an ALV light-scattering instrument equipped with an ALV5000/60X0 Multiple Tau Correlator and an Oxxius SLIM-532 150 mW diode pumped solid state (DPSS) laser operated at a wavelength of 532 nm. A refractive index matching bath of filtered cis-decalin surrounded the cylindrical scattering cell, and the temperature was controlled at 21.5 ± 0.3°C using a Haake F3-K thermostat. For each sample the auto-correlation function, g 2 (Τ), was recorded ten-times at a detection angle of 90°. For each measurement, the diffusion coefficient, D, was determined using the second order cumulant and the corresponding particle diameter was calculated assuming that the particles were spherical in shape. ζ potential of particles was determined on a Malvern ZetaSizer 2000 (UK).
Cells
Granulocytes and peripheral blood mononuclear cells were obtained from buffy coats of healthy individuals and were purified using Ficoll density centrifugation. Peripheral blood lymphocytes (PBLs) and immature DCs (iDCs) were obtained from peripheral blood mononuclear cells of healthy donors after informed consent as reported elsewhere [18] . Female C57BL/6J mice, 8-10 weeks of age, were handled according to European legislation (86/609/ EEC) as previously described [19] . All the experiments and procedures were approved by the Ethics Committee of the Leiden University Medical Center and have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. Splenocytes were isolated by mashing mouse spleen using a 100 μm cell strainer in ice-cold phosphate-buffered saline (PBS) buffer. Cells were spun at 400 × g for 5 min and cell pellet resuspended in ammonium-chloride-potassium (ACK) lysing buffer (8.29 g NH 4 Cl, 1 g KHCO 3 , 37.2 mg Na 2 -EDTA in 1 l water) for 5 min to lyse red blood cells. Nine volumes of culture medium were added to the cells, followed by spinning at 400 × g for 5 min. and the cell pellet resuspended in culture medium. Mouse BMDC were cultured published previously [20] .
Degradation kinetics of free soluble & encapsulated antigen within the NPs iDCs were cultured (10 5 cells/well) in 100 μl X-VIVO 15 medium lacking phenol red (Cambrex) and supplemented with 2% human serum in the presence of 0.5 μg free DQ-BSA and encapsulated in NPs. After 2 h at 37°C, the medium containing NPs and free DQ-BSA that had not been taken up was collected. The cells were cultured at 37°C for 96 h and the fluorescence released within DCs was measured (excitation: 485 nm; emission: 530 nm) in a microplate fluorescent reader CytoFluor II (Applied Biosystems) at various time points. Ag degradation kinetics was determined as described previously [16] .
Uptake kinetics of NPs & soluble antigen by human iDCs & mouse macrophages using flow cytometry 20 μg/ml of PLGA-encapsulated or soluble antigen (FITC-TT) was added to cells (RAW 264.7 and iDC) and incubated at 37°C for a certain amount of time (1, 2, 4, 24 and 48 h). The cells were washed and mean cell-associated fluorescence was determined by flow cytometry on a FacsCalibur (Becton Dickinson, USA).
Uptake kinetics of NPs versus soluble antigen within human iDCs over time using confocal microscopy
Human monocyte-derived iDCs were cultured on fibronectin-coated coverslips in the presence of 20 μg/ ml of particle-encapsulated or soluble FITC-TT peptide for 2, 24, 48 or 96 h. Cells were fixed with 2% paraformaldehyde, washed and incubated with 3% BSA, 10 mM glycine and 1% human serum to prevent nonspecific binding of primary antibodies. After paraformaldehyde fixation and saponin permeabilization, cells were stained with Abs recognizing lysosomes (anti-LAMP1, L1418, rabbit IgG) and early endosomes (anti-EEA1, mIgG1) or isotype control Abs for 30 min at 4°C. After the cells were washed three-times with PBS, Abs were detected with isotype-specific Alexaconjugated secondary Abs. Coverslips were covered with Mowiol and analyzed using an Olympus FV1000 Confocal laser scanning microscope. Images were processed with NIH ImageJ version 1.44a software [41] .
NPs versus soluble antigen within mixed cell populations
Experiments were performed using human blood cells or mouse splenocytes. Human PBL isolated from buffy coats were mixed with iDCs in a 20:1 ratio in culture medium. Cells were incubated with encapsulated or soluble FITC-TT peptide (50 μg/ml) at 37°C for 4 h. Cells were washed and stained with a mannose receptor-specific antibody (clone 19.2, Becton Dickinson) or isotype control antibody to specifically detect DCs. Subsequently, cells were analyzed by flow cytometry on a FacsCalibur.
Splenocytes were isolated by mashing the mouse spleen using a 100 μm cell strainer in ice-cold PBS buffer. Cells were spun at 400 g for 5 min and the cell pellet was resuspended in ACK buffer (8.29 g NH 4 Cl, 1 g KHCO 3 , 37.2 mg Na 2 -EDTA in 1 L water) for 5 min to lyse red blood cells. Nine volumes of culture medium were added to the cells, followed by spinning at 400 × g for 5 min and the cells were resuspended in culture medium. Encapsulated or free antigen was incubated with the splenocytes to study the interactions with distinct cell types, the cells were cultured for 4 h at 37°C in the presence of particles containing FITC-TT peptide or free FITC-TT peptide. Natural killer cells were stained with NK 1.1 PE (1:100) (eBioScience Inc., CA, USA), B cells with B220-PerCP (1:100), DC with CD11C-PE Cy7 (1:200) (Biolegend), macrophages with F4/80-A647 (1:200), and CD8 + T cells with CD8 APC-H7 (1:400).
Uptake kinetics of NPs harboring SPIO within DCs by TEM
DCs were incubated with NPs containing SPIO for 2, 24, 48 and 96 h and fixated with 2% glutaraldehyde/0.1 mol/l sodium cacodylate buffer (pH 7.3). Then, the cells were rinsed in 0.1 mol/l sodium cacodylate buffer, postfixed in 1% OsO4/0.1 mol/l sodium cacodylate buffer, rinsed in 0.1 mol/l sodium cacodylate buffer and spun down in 2% agar/0.1 mol/l sodium cacodylate buffer. The cell pellet was cut in small cubes, dehydrated through graded alcohol and embedded in Agar 100 resin (Agar Scientific Limited, England). Ultrathin sections were cut on a Leica Reichert Ultracut S picked up on formvar coated copper grids, contrasted with uranyl acetate and lead citrate and examined with a Jeol 1010 transmission electron microscope (Jeol, Akishima Tokyo, Japan). Images were taken on Imaging plates (Ditabis) or with a CCD Megaview III (SIS) camera (Münster, Germany).
DC maturation & activation kinetics
Human iDCs (1 × 10 5 iDCs) were plated and incubated in the presence of soluble R848 (5 μg/ml) or NPs encapsulated R848 (5 μg/ml) at 24, 48, 72, 96 or 120 h). After incubation supernatants were harvested and cytokine levels were determined by fluorescent bead immunoassay (Flow Cytometry human Th1/Th2 11plex kit; Bender MedSystems GmbH, Germany). DCs were isolated and stained for maturation markers CD80, CD83, CD86, CCR7, MHC class I and II, and analyzed by flow cytometry. Relative expression levels were determined by dividing mean fluorescent intensities of experimental samples by those of untreated iDCs.
Antigen presentation kinetics iDCs and PBLs of donors that respond to TT-antigen were obtained from buffy coats after informed consent. iDCs were incubated with NPs containing FITC-TT peptide and soluble FITC-TT at distinct time-point 24, 48, 72, 96 and 120 h at 37°C. Following washing, the TT-responsive PBLs were added to the DCs (1:10 hDC/T-cells relationship). Four days after addition of the PBLs, proliferative responses were determined by adding tritiated thymidine (1 μCi [0.037 MBq]/well; MP Biomedicals, Amsterdam, the Netherlands) to the cell cultures. Tritiated thymidine incorporation was measured after 16 h in a scintillation counter.
Antigen presentation kinetics in mouse BMDCs
Day 8 mouse BMDCs were cultured at 5000 cells/well with 50,000 OT-I cells/well and distinct time-point of incubation of NPs harboring OVA (1 μg/ml) and soluble OVA (10 μg/ml) form. To determine T-cell proliferation, tritiated thymidine (1 μCi [0.037 MBq]/ well; MP Biomedicals, the Netherlands) was added to the cell cultures. Tritiated thymidine incorporation was measured after 16 h in a β-scintillation counter.
Statistics
Data were analyzed by one-way ANOVA followed by Newman-Keuls post-test or a two-way ANOVA followed by Bonferroni post-test. The release and degradation of the selfquenching model protein antigen DQ-bovine serum albumin (BSA) encapsulated within PLGA particles versus soluble DQ-BSA was measured for 12 days in live cells in a microplate fluorescent reader (cytofluor II). Particles that had not been taken up within 4 h after incubation with immature dendritic cells were removed to exclusively measure fluorescence generated by degradation of DQ-BSA released from particles located inside the cells. Antigen degradation is expressed as the percentage of fluorescence measured at various time-points relative to the total amount that could theoretically be generated upon full degradation of DQ-BSA (filled boxes). Negative control comprises soluble DQ-BSA incubated in the absence of cells (empty boxes) to detect spontaneous dequenching. DQ-BSA encapsulated in PLGA NP (filled circles). Data represents the mean value ± SD from three independent experiments performed in triplicate. 
Results
Nanoparticle preparation
Various PLGA NP preparations were generated to study different functional aspects of NP uptake, antigen and adjuvant release and their effect on antigen presentation and DC activation over time. NP size ranged between 250 and 400 nm and all NPs were negatively charged (Table 1) . Scanning electron microscopy analysis of NPs revealed spherical particles with uniform size distribution ( Figure 1A ).
Degradation kinetics of free soluble & encapsulated antigen
DQ Green BSA is a derivative of bovine serum albumin (BSA), so heavily labeled with fluorescent BODIPY dye that the fluorophore is self-quenched. The use of DQ-BSA is useful for the visualization of intracellular proteolytic activity. Digestion results in dequenching and the released protein fragments are brightly fluorescent, pH insensitive and show extremely low background fluorescence.
In order to study the kinetics of degradation of encapsulated and soluble DQ-BSA, fluorescence was analyzed following endocytosis of DQ-BSA by DCs [16] . Quenching is relieved by hydrolyses of the protein by cellular proteases into fluorescent peptides. Using pulse-chase experiments in human DCs, fluorescence from DQ-BSA degradation was analyzed for Kinetic antigen release boosts immune response Research Article 12 days. Soluble DQ-BSA was completely degraded 6 days following uptake by DCs, whereas encapsulated DQ-BSA was slowly released (around 20% after 6 days) and degraded over time in a controlled fashion reaching a plateau after 8 days. As expected, almost no antigen degradation was detected when NPs were incubated in culture medium without cells ( Figure 1B Figure 2A) . Similar results were observed using mouse RAW 264.7 macrophages under the same experimental conditions. In case of RAW macrophages, the maximum FITC-TT capture was lower than for iDCs. Fraction of FITC+ iDCs was 50% for NPs versus 45% for free FITC-TT at 48 h. However, higher differences were observed at 24 h (47 vs 32%) and at earlier time points (Figure 2B ), suggesting that the system is almost saturated at 24 h for FITC-TT NPs, but not for its soluble counterpart in both types of cells. In general, encapsulation of antigen in NPs facilitated internalization by iDCs and protected the antigen from extracellular degradation, thereby increasing delivery efficiency.
Uptake kinetics of NPs versus soluble antigen analyzed by confocal microscopy
A confocal microscopy was used to further analyze the intracellular trajectory and persistence of the fluorescence of NPs versus soluble antigen over time. To this end, human monocyte-derived DCs were incubated with NPs harboring FITC-TT peptide or free soluble FITC-TT peptide (green) for 2, 24, 48 and 96 h. Subsequently, cells were fixed, permeabilized and stained with specific antibodies directed against lysosomal-associated membrane protein 1 (LAMP1) (red), and early endosomes (anti-EEA1) (blue), or with an isotype-matched control antibody (data not shown). Merged confocal laser scanning microscope images (Figure 3 ) represent mid focal planes of iDCs. In case of free FITC-TT peptide, the green fluorescent signal was lost or appears as yellow color entirely localized to the lysosomal LAMP1+ compartment over time ( Figure 3A) . Moreover, the signal appeared diffuse, suggesting degradation of the free FITC-TT peptide, while particles harboring FITC-TT peptide showed a confined green fluorescent signal from 2 up to 96 h, suggesting a more gradual delivery of the antigen to cytosolic compartments ( Figure 3B ) [21, 22] . We quantitated the associated fluorescence with software for image analysis and observed that a large percent of fluorescent soluble antigen was contained over time mainly within the lysosomal compartment (LAMP1+). While NPs harboring antigen showed low percent of fluorescence and the antigen did not co-localize with endosomal/lysosomal compartments, indicating that the majority of associated fluorescent antigen had presumably escaped to the cytosol over time ( Figure 3C ). Interestingly and currently under investigation, the green fluorescence signal is not dispersed in the cytosol, but rather concentrated in specific areas, possibly associated with endosomes and the endoplasmic reticulum.
Uptake kinetics of NPs harboring SPIO within iDC analyzed by TEM
The incorporation of SPIO within PLGA NPs has been shown useful to unravel intracellular routing by transmission electron microscopy (TEM) [21, 22] . Therefore, iDCs were incubated with NPs containing SPIO for different time points (2, 24, 48 and 96 h) and then fixed and analyzed TEM (Figure 4 ). The NPs harboring SPIO could be distinguished by their morphology from intracellular organelles. At distinct time points, part of the NPs could be found in endocytic vesicles. A proportion of the SPIO was released from the NPs and associated with endosomal or lysosomal membranes. Some particles also appeared to be localized close to, or within, the vesicle membrane at the endosomal/ cytosolic interface. Especially after longer periods of time, SPIO particles were detected in the cytoplasm ( Figure 4A ) (24-96 h). Quantification of NPs at different subcellular compartments suggests that the majority of the NPs escaped from endosomal/lysosomal compartments to the cytosol over time ( Figure 4B ).
Preferential uptake of NPs versus soluble peptide by human & mouse mixed blood cell populations
To study which cell types preferably take up NPs (via phagocytosis/endocytosis) or soluble peptide (via passive membrane diffusion, or pinocytosis), human peripheral blood mononuclear cells and in vitro differentiated iDCs obtained from buffy coats were mixed (ratio 20:1) and cultured for 4 h at 37°C in the presence of NPs containing FITC-TT peptide ( Figure 5A ; black bars) or free FITC-TT peptide ( Figure 5A ; grey bars). iDCs were detected using antibodies directed against the mannose receptor and monocytes and lymphocytes based on their size and granularity by flow cytometry. The relative fluorescence of the mannose receptor positive (DC) and negative (other blood leu- Quantification of NPs at distinct subcellular compartments over time (1) some NPs also appeared to be localized close to, or within, the vesicle membrane at the endosomal/lysosomal membranes; (2) a proportion of the SPIO was already released from NPs; (3) other NPs were localized freely within the cytoplasm. Differences between NPs at the endosomal/lysosomal compartment and NPs within the cytoplasm compartment were analyzed applying student unpaired t-test. *p < 0.05; ***p < 0.001. [23] . Particulate antigen was preferred by iDCs with respect to soluble peptide. A similar behavior was observed among other leukocytes, in which the FITC-TT fluorescence signal was associated mainly with monocytic cells (monocytes + DCs).
When the same study was performed with mouse splenocytes (Figure 5B ), cells were cultured for 4 h at 37°C in the presence of NPs containing FITC-TT peptide ( Figure 5B -black bars) or free FITC-TT peptide ( Figure 5B -grey bars) . To study which type of cell preferably takes up NPs or soluble peptide, cells were stained with cell type-specific markers. Once again, particulate antigen was highly preferred over free peptide by all cell types. However, the fluorescent signal derived from encapsulated FITC-TT was mainly associated with macrophages and iDCs, indicating that these cell types are the main phagocytes in the spleen.
Antigen presentation kinetics of human & mouse DCs following uptake of NPs versus soluble antigen
Human monocyte-derived DCs were cultured in the presence of NPs harboring FITC-TT peptide (0.5 μg/ ml of peptide) and FITC-TT peptide (0.5 μg/ml) for 24, 48, 72, 96 or 120 h ( Figure 6A) . As a control, iDCs were cultured with empty particles. At the indicated times, autologous TT-responsive PBLs were added and CD4+ T-cell proliferation was measured after 4 days by tritium thymidine incorporation assay [21] . Particulate antigen induced T-cell proliferation at 24 h postantigen challenge. After 24 h, T-cell proliferation was progressively reduced, but could be detected up to 120 h. Contrarily, soluble antigen induced significantly less T-cell proliferation ( Figure 6A ). The same experiment was performed using mouse BMDCs and mouse T cells specifically recognizing OVA antigen [24] [25] [26] [27] [28] . Mouse BMDCs were incubated with NPs harboring OVA protein or soluble OVA protein at distinct incubation times, as indicated ( Figure 6B & C) . Antigen presentation via MHC classes I and II was determined following incubation of mouse BMDCs with OT-I (CD8 + ) and OT-II (CD4 + ) T cells with NPs harboring OVA, or soluble OVA protein. Two independent experiments were performed showing similar results. Particulate OVA antigen induced stronger T-cell proliferation at all studied time points than soluble OVA, both for CD4 + ( Figure 6B ) and CD8 + cells ( Figure 6C ). The kinetics of OVA antigen presentation follows a similar shape in both NP encapsulated and soluble OVA in all performed assays, but always with significant differences in favor of OVA encapsulated in NPs, Kinetic antigen release boosts immune response Research Article even though the soluble OVA was added in tenfold excess. These results suggest a more effective uptake and antigen processing, as observed in the assays presented above, and a prolonged availability or delivery of the NP encapsulated antigen. These results indicate that NPs serve as an intracellular antigen reservoir capable of providing a steady and prolonged source of antigen for both human and murine DCs, increasing both the efficiency and duration of MHC class II and I cross-presentation.
DC maturation & activation kinetics after exposure to NP-encapsulated or soluble TLR ligand
The capacity of NPs carrying TLR ligands to induce maturation DCs was determined by analyzing the induction of DC surface markers CD80, CD83, CD86, CCR7, MHC class I and II by flow cytometry at the indicated times (Figure 7 ). DCs were cultured with NPs containing R848 (5 μg/ml final concentration) or soluble R848 (5 μg/ml final concentration). Untreated DCs and DCs cultured with NPs (empty) without TLR ligands were used as negative controls. Relative expression levels of activation markers were determined by dividing mean fluorescent intensities of experimental samples by those of untreated DCs.
A progressive increase of all the maturation/activation markers studied was observed until 120 h. The results showed that the DC maturation markers were significantly different expressed at all-time points when using NPs encapsulated R848 with respect to the soluble form (Figure 7 ). The kinetics of surface marker expression follows a similar shape in both NP encapsulated and soluble R848 in all markers studied, but marker expression declined earlier with soluble R848 than R848 encapsulated NP, which presented a prolonged time of activation, suggesting a longer availability or delivery of the NP encapsulated R848 into DCs.
In the same experiment, supernatants were harvested at each time point to determine cytokine levels upon R848 challenge (Figure 8 ). The profile of the cytokines IL-6, IL-8, IL-12 and TNF-α followed a similar pattern as was observed for the DC maturation markers. In the presence of NPs containing R848, a progressive increase of IL-6, IL-8, IL-12 and TNF-α production was observed over time with significant differences regarding the soluble R848 form. Moreover, with soluble R848 the levels of cytokine production diminished sharply at 96 and 120 h (Figure 8) . Empty NPs or nonstimulated DCs (DCs alone) served as negative controls and showed at most negligible levels of cytokine production or expression of maturation/ activation markers (Figures 7 & 8) .
Discussion
Cancer therapeutics such as chemotherapy is often associated with serious side effects. Therefore, during the past decade a great effort was invested to develop novel effective therapies such as immunotherapy. Boosting the immune system to fight cancer is performed by antibodies or cytotoxic T cells that are highly specific against the tumor and preventing serious side effects [29] . Theoretically, the human immune system has the capacity to eradicate pathogens and cancer cells. However, efforts to develop effective cancer vaccines have been largely disappointing. Ideally, cancer vaccines should ultimately achieve a similar level of success as that obtained with vaccines against infectious agents [30] . There are several facts that could explain the inefficiency of cancer vaccines: Tumor cells are in a general sense very similar to normal cells and only mutations or aberrant expression of some genes could be recognized as tumor antigens, which are poor immunogens; additionally, genetic variability in tumor evolution could induce loss of tumor antigens. Therefore, it is important in cancer vaccine designs to include multiple antigens to avoid tumor immune escape. Furthermore, it is also important to introduce adjuvants, such as TLR ligands that strongly activate and mature APC, to 'trick' the immune system into believing that it is facing an infectious agent to induce a strong immune response. On the other hand, the use of soluble cancer antigens may be dispersed throughout the body fluids reducing its half-life and soluble adjuvants might activate inappropriate (nonantigen presenting) cells resulting in cytokine-related toxicity. Human monocyte-derived DCs were cultured in the presence of PLGA NPs containing R848 (5 μg/ml) versus soluble R848 (5 μg/ml). Following distinct incubation times, the supernatants were harvested to determine cytokine production levels. As a control, DCs were cultured with empty PLGA NPs. Two independent experiments were performed using iDCs from different donors. Data represent mean cytokine expression levels of one representative experiment performed in duplicate ± SD. Statistical analysis was performed using the two-way ANOVA with Bonferroni post-test. ***p < 0.001; **p < 0.01; *p < 0.05. The idea that slow release of antigens and adjuvants in a vaccine is beneficial by prolonging the interaction of antigen with the immune system, has been present for many years in vaccinology studies, without a clear demonstration. Intuitively, this was based on results of the use of alum salts as adjuvants. The argument was that alum salts per se are relatively week adjuvants and rarely induce cellular immune responses, but they slow down the release of antigen and increase the duration of antigen interaction with the immune system, thus enhancing the immune response. Although the mode of action of these adjuvants was not completely understood, aluminium hydroxide gel and oil emulsions were considered to exert their effects by an extended release from the site of injection [31, 32] . Despite their slow antigen release characteristics and concurrent stimulation of antibody producing plasma cells, most of these adjuvants were based on oil emulsions, like FIA and Montanide, which are too toxic for routine prophylactic vaccine use in human [33] . Furthermore, an understanding of each antigen-adjuvant interaction is essential to ensure compound stability after mixing and to prevent decreasing vaccine efficacy [34] .
In this study, we demonstrated that slow release of antigen and adjuvants is beneficial to the immunological response. We found that antigen internalization via NPs significantly influences the efficiency of antigen uptake and processing; soluble antigens internalized by micropinocytosis are poorly presented, while particulate antigens, which enter cells via phagocytosis/endocytosis, such us NPs, are presented more efficiently. Moreover, some studies suggest that optimal antigen presentation demands that antigens and DC activation stimuli are located in the same intracellular compartment [35] [36] [37] , as ensured by uptake of antigen and adjuvant encapsulated in NPs.
In addition, we showed that slow kinetics of antigen release increased the efficiency of MHC class II and I antigen cross-presentation in both primary human and murine DCs. Furthermore, antigen presentation mediated by NPs persisted much longer than by soluble antigen, indicating that this method of antigen delivery could significantly improve and prolong T-cell stimulation. These results are in line with recent studies that indicated that particles loaded with antigenic peptide or pathogen-associated proteins are capable of inducing robust, specific CTL response [38] [39] [40] 22, 21] . Another finding represents the capacity of NPs loaded with TLR ligand to increase cytokine production, maturation and activation of DCs with respect to the soluble TLR ligand. These results indicate that the slow-release and delivery of TLR ligand into the cytoplasm can promote optimal adjuvant presentation, a key factor in increasing the potency of vaccines against tumor and infectious agents. An increasing knowledge of the mechanisms of antigen processing, DC activation and antigen presentation in the context of MHC class I and II as well as negative regulation of the immune response induced by tumors has allowed the development of new tumor vaccines.
Our results also provide strong evidence that the observed increase in antigen presentation, maturation stimulus and cytokine production is sustained in a prolonged manner due to the superiority of the NPs in slow and controlled release compared with soluble antigen (Figure 1) and that particulated systems such as PLGA NPs facilitate endosomal/lysosomal escape of distinct payloads to the cytosol (Figures 3 & 4) . This biochemical confirmation is in line with previous reports which indicated microscopically that NPs did not co-localize with the endo/lysosomal compartments [21, 22] .
Conclusion
PLGA-encapsulated antigens and adjuvants showed an increased antigenicity and adjuvanticity, which outcompeted their soluble counterparts. Even though the kinetics of uptake, antigen presentation, maturation and activation, and cytokine production presented a parallel behavior, encapsulated agents consistently produced stronger responses that persisted longer than the soluble agents. This highlights the superiority of particulate vaccine formulations for development of next generation therapeutic vaccines. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
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Executive summary Background
• Dendritic cells (DCs) are the key antigen presenting cells capturing nanoparticles (NPs) for anticancer vaccines.
However, it is yet unknown whether a slow release of antigen and adjuvant as determined from vaccine nanocarriers is superior compared with vaccine components freely deposited within the tissue.
Methods
• The kinetics of antigen release was studied by means of the self-quenching model protein antigen DQ-BSA encapsulated within PLGA NPs, compared with nonencapsulated DQ-BSA antigen. The effect of controlled antigen and adjuvant release from PLGA NPs on the immunological response was assessed by induction of DC activation/maturation markers, cytokine production and their ability to drive antigen-specific T-cell proliferation.
Kinetic of Ag & adjuvant release influence on immune response
• PLGA-encapsulated antigen and adjuvant showed an enhanced T-cell response when compared with soluble administered vaccine components by increasing antigenicity and adjuvanticity.
Conclusion
• Although the kinetic profile of antigen presentation and cytokine production followed the same pattern for encapsulated and soluble vaccine components as expected, encapsulation increased strength and duration of the response.
